Mirxes Holding Company Limited (SEHK: 2629)
Health Care · Biotechnology · SG
HK$—
— today · — 1Y
Mirxes Holding Company Limited (SEHK: 2629) operates in the Biotechnology industry within the Health Care sector. The company is valued at $467.25M and employs 352 people.
trading between 12.28 and 77.30.
Tweenvest scores Mirxes Holding Company Limited across four factors: value 82/100. Its strongest factor is value.
2629 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $467.25M
- Revenue (TTM)
- $21.19M
- P/E
- —
- EPS
- -0.56
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$77.30
- 52-week low
- HK$12.28
- Avg volume (3M)
- —
- Shares outstanding
- 295.19M
- Employees
- 352
- Next earnings
- —
About Mirxes Holding Company Limited
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related products. The company was founded in 2014 and is headquartered in Singapore.
- ISIN
- KYG6152E1052
- Founded
- 2014
- Listed since
- May 23, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.13 | -1.75% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.39 | -0.19% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.54 | -0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.64 | -0.58% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $823.30 | -1.23% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $146.41 | -7.82% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.